IISER Bhopal Hosts Dr. Anil Koul for Lecture on Groundbreaking TB Drug Bedaquiline

The Indian Institute of Science Education and Research (IISER) Bhopal recently hosted an illuminating lecture by Dr. Anil Koul, Vice President of Research at Johnson & Johnson, titled “Discovery of Bedaquiline and its Impact on Global Tuberculosis Landscape.” The event drew an enthusiastic audience of students, faculty, and researchers, all eager to gain insights into one of the most significant medical breakthroughs in the fight against tuberculosis (TB).

Dr. Koul, a leading figure in pharmaceutical research, played a pivotal role in the discovery and development of Bedaquiline — the first novel TB drug approved in over four decades. During the session, he detailed the scientific journey behind the drug’s development, from initial research and clinical trials to its global deployment in treating multi-drug-resistant tuberculosis (MDR-TB).

Highlighting the challenges faced during development, Dr. Koul emphasized the importance of perseverance, cross-disciplinary collaboration, and innovation in translating basic science into life-saving therapies. He also shed light on the socio-economic and public health impacts of Bedaquiline, particularly in high-burden countries, including India.

The lecture served not only as a deep dive into drug discovery but also as an inspiration for the next generation of scientists. Students engaged in an interactive Q&A session, discussing scientific, ethical, and logistical aspects of pharmaceutical research.

Dr. Koul’s visit underscored IISER Bhopal’s commitment to fostering a culture of scientific curiosity and global health awareness. The session was widely appreciated as a valuable learning opportunity and a motivating reminder of science’s power to transform lives.